Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation

Bone Marrow Transplant. 2004 Apr;33(7):769-71. doi: 10.1038/sj.bmt.1704419.

Abstract

Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here, we report details of a 29-year-old woman treated successfully by donor lymphocyte infusions (DLIs) following allogeneic HSCT for acquired refractory relapsed PRCA. The nonmyeloablative conditioning regimen consisted of cyclophosphamide 60 mg/kg/day for 2 days and fludarabine 30 mg/m(2) daily for 4 days. Haematopoiesis was still completely 'recipient' 1 month after allo-HSCT, but progressed to full donor engraftment after three doses of 'escalating' DLI. The possible role of a graft-versus-autoimmunity effect induced by allogeneic HSCT followed by DLI infusions in the treatment of the disease is discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphocyte Transfusion*
  • Peripheral Blood Stem Cell Transplantation*
  • Recurrence
  • Red-Cell Aplasia, Pure / therapy*
  • Remission Induction / methods
  • Salvage Therapy / methods*
  • Transplantation Chimera
  • Transplantation Conditioning / methods
  • Transplantation, Autologous
  • Transplantation, Homologous